EBS vs KEY · rev $1.04B vs P/E 13, rev $7.51B
Emergent Biosolutions Inc (EBS) versus KeyCorp (KEY) — a side-by-side from cached financials, not a winner call.
Emergent Biosolutions Inc (EBS) is a drug manufacturers - specialty & generic company listed on US.
KeyCorp (KEY) is a banks - regional company listed on US.
Latest reported EBS revenue for 2024-12-31 was $1.04B. Net income was -$190.6M. Revenue was down 0.5% from 2023-12-31 to 2024-12-31. EBS currently screens at market cap $416.4M.
Latest reported KEY revenue for 2025-12-31 was $7.51B. Net income was $1.83B. Revenue was up 62.7% from 2024-12-31 to 2025-12-31. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
EBS currently screens at market cap $416.4M. KEY currently screens at market cap $22.64B and trailing P/E 12.8.
Not investment advice. Open the EBS and KEY stock pages for the full models.
Not investment advice.